Rohto Pharmaceutical Co.,Ltd.
RPHCF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $569 | $551 | $552 | – |
| % Growth | 3.1% | -0.1% | – | – |
| Cost of Goods Sold | $254 | $250 | $235 | – |
| Gross Profit | $315 | $302 | $317 | – |
| % Margin | 55.3% | 54.7% | 57.4% | – |
| R&D Expenses | $23 | $22 | $22 | – |
| G&A Expenses | $0 | $0 | $0 | – |
| SG&A Expenses | $210 | $236 | $203 | – |
| Sales & Mktg Exp. | $0 | $0 | $0 | – |
| Other Operating Expenses | $0 | $0 | $0 | – |
| Operating Expenses | $234 | $258 | $226 | – |
| Operating Income | $81 | $44 | $91 | – |
| % Margin | 14.2% | 7.9% | 16.5% | – |
| Other Income/Exp. Net | $24 | $7 | $12 | – |
| Pre-Tax Income | $105 | $50 | $103 | – |
| Tax Expense | $21 | $8 | $28 | – |
| Net Income | $82 | $41 | $76 | – |
| % Margin | 14.4% | 7.5% | 13.7% | – |
| EPS | 0.36 | 0.18 | 0.33 | – |
| % Growth | 100% | -45.5% | – | – |
| EPS Diluted | 0.36 | 0.18 | 0.33 | – |
| Weighted Avg Shares Out | 226 | 226 | 228 | – |
| Weighted Avg Shares Out Dil | 229 | 229 | 229 | – |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | – |
| Interest Expense | $2 | $3 | $3 | – |
| Depreciation & Amortization | $28 | $31 | $26 | – |
| EBITDA | $135 | $84 | $132 | – |
| % Margin | 23.8% | 15.2% | 23.9% | – |